Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
Earnings Data
Report Date
Apr 30, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-1.3Last Year’s EPS
-2.77Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a mixed but measured outlook: strong near‑term clinical catalysts (SENTRY in March and EXPORT EC042 mid‑2026), encouraging early efficacy and tolerability data, modest product revenue growth and demonstrated cost discipline. Offsetting these positives are a constrained cash runway (into Q2 2026), large GAAP losses driven by debt‑related and noncash items, elevated interest expense, and dependence on binary Phase III readouts to drive future value. Overall, the balance of significant upside potential from pending pivotal data against material near‑term financial constraints yields a neutral stance.Company Guidance
Upcoming Pivotal Phase III Readouts
Top-line data for Phase III SENTRY (myelofibrosis) expected in March 2026 and Phase III EXPORT EC042 (endometrial cancer) expected mid-2026 — both positioned as potential practice‑changing events and primary near‑term value drivers for the company.
Compelling Early Clinical Signals
Phase I combination data reported an SVR35 of ~79% versus ~33% with ruxolitinib historical data; absolute TSS improvement of 18.5 points (week 24) versus 11–14 reported with ruxolitinib in prior trials; early blinded SENTRY safety signals suggest lower rates of grade 3+ anemia and manageable non‑heme toxicities.
Commercial Performance and 2026 Revenue Guidance
Q4 2025 U.S. XPOVIO net product revenue of $32.1M (up 9.6% YoY) and full‑year 2025 U.S. XPOVIO net product revenue of $114.9M (up 1.9% YoY). Total revenue Q4 $34.1M (up 11.8% YoY) and full‑year total revenue $146.1M (slight increase vs 2024). 2026 guidance: U.S. XPOVIO net product revenue $115M–$130M; total revenue $130M–$150M.
Disciplined Operating Cost Reductions
Research & development expense decreased 17% Q4 and 12% for full‑year 2025 (Q4 R&D $27.7M; FY R&D $125.6M). Selling, general & administrative expenses decreased 16% in Q4 and 9% for the full year (Q4 SG&A $22.8M; FY SG&A $105.2M), reflecting cost reduction initiatives and prioritization of late‑stage programs.
Large Addressable Myelofibrosis Opportunity & Commercial Readiness
Company cites ~20,000 prevalent U.S. myelofibrosis patients and ~6,000 new diagnoses annually, focusing on ~4,000 newly diagnosed intermediate‑to‑high risk patients (platelets >100k). Market research indicates 75% physician intent to use a combination regimen; management estimates peak U.S. revenue potential approaching $1 billion.
Dose Optimization and Improved Tolerability Strategy
Selinexor dose refined to 60 mg weekly for myelofibrosis (higher exposure and efficacy vs 40 mg in Phase I) with mandated dual antiemetics in early cycles; company emphasizes lower dosing/optimized supportive care in MF vs higher doses historically used in multiple myeloma to improve tolerability and adoption.
KPTI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KPTI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 12, 2026 | $7.37 | $8.94 | +21.30% |
Nov 03, 2025 | $5.80 | $6.07 | +4.66% |
Aug 11, 2025 | $3.94 | $3.77 | -4.31% |
May 12, 2025 | $6.15 | $4.92 | -20.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Karyopharm Therapeutics (KPTI) report earnings?
Karyopharm Therapeutics (KPTI) is schdueled to report earning on Apr 30, 2026, TBA (Confirmed).
What is Karyopharm Therapeutics (KPTI) earnings time?
Karyopharm Therapeutics (KPTI) earnings time is at Apr 30, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KPTI EPS forecast?
KPTI EPS forecast for the fiscal quarter 2026 (Q1) is -1.3.